[{"from": "human", "value": "What can you tell me about this molecule? [C][C@@H1][C][C][=C][Branch1][#Branch2][C][C][C][=Branch1][C][=O][C][Ring1][#Branch1][C@@H1][C@@H1][Ring1][O][C@@H1][C][C][C@][Branch1][O][C@][Ring1][Branch1][Branch1][Branch1][C][C][Ring1][=Branch2][C][Branch1][Ring1][C][#C][O]"}, {"from": "gpt", "value": "The molecule is a synthetic steroid hormone drug, which is mainly non-selective in its binding profile, acting as an agonist primarily at estrogen receptors (ER), with a preference for ER alpha.  Tibolone (Livial, Org OD 14), produced by Organon (West Orange, NJ), is a synthetic steroid that possesses estrogenic, androgenic and progestogenic properties. It has been used in Europe for almost 2 decades, primarily for the prevention of postmenopausal osteoporosis and the treatment of post-menopausal symptoms.  Tibolone is approved in 90 countries to manage menopausal symptoms and in 45 countries to prevent the development of osteoporosis.  In June 2006, Organon Pharmaceuticals announced the receipt of a Not Approvable Letter from the U.S. Food and Drug Administration (FDA), advising the company that the New Drug Application (NDA) for tibolone had not been approved.  Interestingly, the use of tibolone in the treatment cardiovascular disease has been studied with inconclusive results. Tibolone has been to have anti-resorptive effects on bone."}]